Trials / Completed
CompletedNCT01687400
Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
Genomic Predictors of Decitabine Response in AML/MDS
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 114 (actual)
- Sponsor
- Washington University School of Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This clinical trial studies potential genetic markers which might be used to predict which patients with acute myeloid leukemia or myelodysplastic syndromes respond to decitabine. This study will contribute to the efforts to find effective and less toxic therapies to provide durable remissions in a significant proportion of elderly AML patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | decitabine |
Timeline
- Start date
- 2013-02-12
- Primary completion
- 2017-06-23
- Completion
- 2017-11-13
- First posted
- 2012-09-18
- Last updated
- 2018-10-02
- Results posted
- 2018-10-02
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT01687400. Inclusion in this directory is not an endorsement.